Business Wire

CA-ANDERSEN-GLOBAL

Del
Andersen Global går ind i New Zealand og tilføjer to samarbejdende virksomheder

Andersen Global etablerer skattemæssige og juridiske kompetencer i New Zealand gennem samarbejdsaftaler med to virksomheder beliggende i Auckland – advokatfirmaet Turner Hopkins og skatte- og rådgivningsfirmaet Bellingham Wallace. Virksomhederne opretholder solide forbindelser i regionen og vil spille en central rolle i at drive forretning og levere integrerede, globale løsninger for at skabe langsigtet værdi for kunderne.

Turner Hopkins blev grundlagt i 1923 og har i næsten 100 år leveret fuldservice-kompetencer inden for ejendomsret, selskabs- og erhvervsret, procesførelse, finans, ansættelsesret, familieret, private kunder, ejendoms- og immigrationsret. Turner Hopkins’ tværfaglige team af fagfolk har stor erfaring med at arbejde på tværs af en række brancher og tage sig af kundernes behov med omfattende, skræddersyede løsninger.

”Vi er stolte over vores kundefokuserede tilgang og vores forpligtelse til at sikre, at vi fastholder den højeste kaliber af advokater og fagfolk, hvilket har gjort det muligt for os at opretholde en konkurrencefordel i Auckland-regionen i næsten et århundrede,” siger ledende partner Michael Robinson. ”Samarbejdet med Andersen Global gør os i stand til fortsat at arbejde problemfrit med kunder og levere kvalitetsløsninger til kunder med stigende globale behov”.

Bellingham Wallace blev etableret i 2012 og grundlagt af to ledende partnere Matt Bellingham og Aaron Wallace, for at arbejde tæt sammen med kunder lige fra små til store privatejede virksomheder. Virksomheden tilbyder en række fuldservice-kompetencer inden for rådgivning, ledelse, skat, strategi, due diligence og værdiansættelse for at drive vækst og styre risici for kundernes virksomheder.

”Vores virksomhed har oplevet enestående vækst i løbet af de seneste par år, alt imens vi fortsætter med at prioritere alle vores kunders behov og udvide vores eksisterende kapaciteter på markedet,” siger medgrundlægger og ledende medpartner Matt Bellingham. ”Samarbejdet med Andersen Global viser vores forpligtelse til ekspertise og styrker vores kundefokuserede tilgang, da de yderligere globale ressourcer vil styrke vores evne til at imødekomme kundernes skiftende behov,” tilføjer Aaron Wallace.

Andersen Globals bestyrelsesformand og CEO Mark Vorsatz siger: ”Turner Hopkins og Bellingham Wallace vil være store aktiver i vores bestræbelse på at imødekomme vores voksende behov i regionen. Disse virksomheder deler vores organisations engagement i ledelse og udviser de højeste professionelle standarder, og vi forudser et synergistisk samarbejde mellem vores fagfolk. Det er vigtigt for os at samarbejde med disse virksomheder, mens vi fortsat giver klassens bedste løsninger til vores kunder over hele kloden og styrker vores tilstedeværelse i Asien og Stillehavsområdet.”

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsvirksomheder, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013, og Andersen Global har nu over 11.000 fagfolk på verdensplan og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye